Reference : Does lobar or size-reduced lung transplantation offer satisfactory early and late out...
Scientific journals : Article
Human health sciences : Surgery
http://hdl.handle.net/10993/45782
Does lobar or size-reduced lung transplantation offer satisfactory early and late outcomes?
English
Silva, João Santos [Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France > Service de Chirurgie Thoracique]
Olland, Anne [Hôpitaux Universitaires de Strasbourg, Strasbourg, France > Service de Chirurgie Thoracique, Nouvel Hôpital Civil > > ; INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France]
Massard, Gilbert mailto [University of Luxembourg > Faculty of Science, Technology and Medicine (FSTM) > Department of Life Sciences and Medicine (DLSM) > ; Hôpitaux Universitaires de Strasbourg, Strasbourg, France > Service de Chirurgie Thoracique, Nouvel Hôpital Civil]
Falcoz, Pierre-Emmanuel [Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France > Service de Chirurgie Thoracique > > ; INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France]
24-Apr-2020
Interactive Cardiovascular and Thoracic Surgery
Elsevier
Yes (verified by ORBilu)
International
1569-9293
1569-9285
Netherlands
[en] Donor pool ; Size reduced ; Lung transplantation
[en] A best evidence topic was constructed according to a structured protocol. The question addressed was whether size-reduced or lobar lung transplantation (LLTx) offers the same benefit as classic lung transplantation (LTx). Of the 147 papers found using the reported search, 9 were selected to provide the best evidence. Details of the studies regarding authors, date, journal, country of publication, study type, group studied, relevant outcomes and results are given. All studies reported survival rates of LLTx and most compared it with classical LTx. No statistical differences were reported in medium term and long term. Two of the studies reported a higher incidence of postoperative complications, such as the need for cardiopulmonary bypass, reperfusion oedema or primary graft dysfunction, and longer intubation or intensive care unit stay times. Although the largest study showed a significantly worse 1-year survival in LLTx, a sub-analysis considering patients successfully discharged showed similar outcomes at 1, 3 and 5 years when compared with classic LTx patients. We conclude that LLTx is a valid therapeutic option for recipients with significant donor size mismatch, offering similar outcomes as classical LTx in the medium term and long term.
Researchers ; Professionals
http://hdl.handle.net/10993/45782
10.1093/icvts/ivaa051

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Limited access
Silva et al., 2020.pdfPublisher postprint141.94 kBRequest a copy

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.